Tumor Mutation Burden-From Hopes to Doubts

JAMA Oncol. 2019 Jul 1;5(7):934-935. doi: 10.1001/jamaoncol.2019.0626.

Authors

Alfredo Addeo¹, Giuseppe L Banna², Glen J Weiss³

Affiliations

¹ Oncology Department, Geneva University Hospital, Geneva, Switzerland.
² Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.
³ Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

PMID: 31145420
DOI: 10.1001/jamaoncol.2019.0626

No abstract available

MeSH terms

Antineoplastic Agents / therapeutic use
Biomarkers, Tumor / genetics*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Carcinoma, Non-Small-Cell Lung / mortality
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Lung Neoplasms / mortality
Mutation*
Survival Analysis

Substances

Antineoplastic Agents
Biomarkers, Tumor